Stemtech (STEK) Income from Non-Controlling Interests (2021 - 2025)
Stemtech's (STEK) quarterly Income from Non-Controlling Interests came in at -$3135.0 in Q3 2025, down 238.92% year-on-year from $2256.7 in Q3 2024, and little changed quarter-over-quarter from -$3135.0 in Q2 2025.
Stemtech (STEK) Income from Non-Controlling Interests (2021 - 2025) Analysis & Trends
Stemtech has disclosed Income from Non-Controlling Interests across 5 years of filings, most recently posting -$3135.0 for Q3 2025.
- Income from Non-Controlling Interests for Q3 2025 came in at -$3135.0, down 238.92% year-over-year; the trailing twelve-month figure through Dec 2025 was -$9405.0 (down 200.0% YoY), and the FY2025 annual result was -$3135.0, changed 0.0% from the prior year.
- Income from Non-Controlling Interests came in at -$3135.0 for Q3 2025 at Stemtech, roughly flat from -$3135.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $1707.0 in Q3 2023 to a low of -$30707.0 in Q3 2022.
- The 5-year median for Income from Non-Controlling Interests is -$3566.0 (2023), against an average of -$7545.8.
- Across the five-year window, Income from Non-Controlling Interests surged 105.56% in 2023 and slumped 4643.48% in 2025, its largest moves.
- Stemtech's Income from Non-Controlling Interests stood at -$8649.0 in 2021, then sank by 164.44% to -$22871.0 in 2022, then surged by 103.5% to $800.0 in 2023, then sank by 215.62% to -$925.0 in 2024, then tumbled by 238.92% to -$3135.0 in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$3135.0 (Q3 2025), -$3135.0 (Q2 2025), and -$3135.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Stemtech | - | - | 354,677.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3,135.00 |
| Jun 30, 2025 | -3,135.00 |
| Mar 31, 2025 | -3,135.00 |
| Sep 30, 2024 | -925.00 |
| Jun 30, 2024 | 69.00 |
| Mar 31, 2024 | -2,279.00 |
| Dec 31, 2023 | 800.00 |
| Sep 30, 2023 | 1,707.00 |
| Jun 30, 2023 | -3,997.00 |
| Mar 31, 2023 | -244.00 |
| Dec 31, 2022 | -22,871.00 |
| Sep 30, 2022 | -30,707.00 |
| Jun 30, 2022 | -19,665.00 |
| Mar 31, 2022 | -14,662.00 |
| Dec 31, 2021 | -8,649.00 |
| Sep 30, 2021 | -10,262.00 |
| Jun 30, 2021 | -10,658.00 |
| Mar 31, 2021 | -4,077.00 |